BLOODPAC Announces New Protocols for Liquid Biopsy Tests
Published in JCO Precision Oncology, the latest analytical validation standards introduced by The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium aim to provide a broad protocol for test developers.
The consensus document, recently unveiled, offers comprehensive guidance for analytical validation specifically catered to tumor-informed ctDNA assays for the purpose of monitoring Molecular Residual Disease (MRD). MRD assessments play a crucial role in identifying the molecular signatures linked to residual cancerous activity post-treatment, supporting clinicians in real-time patient monitoring and informed treatment decisions.
This essential manuscript outlines methods such as the "Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation" was developed collaboratively by BLOODPAC's MRD Analytical Validation Working Group. The publication establishes basic protocols aimed to aid organizations in the design and execution of analytical studies for MRD assessments.
As Lauren Leiman, Executive Director of BLOODPAC, sheds light on the initiative, she states, "These protocols reflect a deep collaborative effort and a shared commitment to advancing high-quality, reproducible MRD testing. By providing a unified framework for analytical validation, BLOODPAC is helping to accelerate the development of trustworthy ctDNA MRD assays that will benefit patients."
The protocols are designed not only to streamline how analytical validation studies are conducted but also to address ongoing challenges faced by both test developers and regulators. One of the primary focuses is providing guidelines for assessing critical analytical performance metrics, including limit of blank (LoB), limit of detection (LoD), accuracy, and precision.
Ensuring Robust Assay Performance
Additionally, BLOODPAC's guidelines encompass considerations that may impact assay performance. Factors such as guard banding help enhance assay robustness, stability of specimens during preparation, and shipping, along with evaluating substances that could interfere with test accuracy.
Experts emphasize the importance of evaluating the comparability of contrived samples and clinical samples to ensure that reference materials used in the validation yield similar performances as patient-derived cfDNA samples.
Jonathan Baden, Executive Director & Head of Precision Medicine at a major pharmaceutical company, stated, "MRD is being established as a relevant biomarker across multiple solid tumor malignancies. Developing a unified framework of analytical standards is essential to guarantee these assays are validated quickly, yielding robust and reproducible results, and can be confidently adopted in clinical practice. Driving this new framework forward will enhance patient access to personalized treatments."
The Importance of Collaboration in Development
According to Leiman, "BLOODPAC's goal is to provide developers with a comprehensive foundation for demonstrating the analytical performance of ctDNA MRD assays, regardless of the technology they employ. This practice allows us to shift our focus to what is most important: reliable tests that directly influence patient care."
Composed of a diverse group of specialists from biotech and pharmaceutical sectors, academia, and regulatory bodies, the BLOODPAC MRD Analytical Validation Working Group represents a wealth of expertise. Contributors include prominent figures in molecular diagnostics, bioinformatics, oncology, and regulatory practices, all dedicated to refining MRD testing techniques.
Continuing the Tradition of Standardization
The new analytical protocols herald a continuation of BLOODPAC's commitment to establishing comprehensive industry standards for test validation. Recently, they issued recommendations in the Journal of Molecular Diagnostics, detailing significant technical and biological factors for the analytical validation of blood-based tumor mutational burden (bTMB) assays. These advances hold substantial promise in predicting patient responses to immunotherapy in various advanced and metastatic solid tumors.
Earlier, the consortium published generic analytical protocols in Clinical Chemistry, setting forth baseline standards for the evolution of next-generation sequencing-based ctDNA liquid biopsy tests.
About BLOODPAC
BLOODPAC, a consortium managed by the Center for Computational Science Research, Inc. (CCSR), operates as a not-for-profit organization founded to expeditiously improve the development and validation of liquid biopsy assays for cancer patients. By leading a pioneering collaborative network, BLOODPAC fosters information sharing and consensus building among stakeholders across various sectors, including industry, academia, regulatory bodies, and government agencies.
Contact: Berna Diehl
Frequently Asked Questions
What is BLOODPAC?
BLOODPAC is a consortium that aims to improve liquid biopsy tests and methodologies to enhance cancer treatment outcomes.
What are MRD tests?
Molecular Residual Disease (MRD) tests are designed to assess the presence of cancer remnants following treatment and inform medical decisions based on patient responses.
Why are the new protocols significant?
The newly introduced protocols offer a standardized framework that aids test developers in ensuring the reliability and accuracy of MRD assays.
Who contributed to the new protocols?
The protocols were developed by experts in various fields, including oncology, molecular diagnostics, and regulatory science, representing a broad array of knowledge and experience.
How do these protocols impact patient care?
By establishing validated standards for liquid biopsy tests, the protocols ultimately aim to accelerate the development of reliable tests that can improve patient outcomes in cancer care.
